Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-05-07 18:29 | 2021-05-05 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $34.00 | 1,750 | $59,500 | 593,773 | -0.3% |
| 2021-05-05 21:05 | 2021-05-03 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $34.79 | 2,200 | $76,547 | 210,941 | -1.0% |
| 2021-05-04 22:00 | 2021-04-30 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $35.00 | 1,500 | $52,500 | 593,916 | -0.3% |
| 2021-04-23 03:17 | 2021-04-20 | ARQT | Arcutis Biotherapeutics Inc. | CHAUDHURI BHASKAR | Director | Pharmaceutical Preparations | SALE | $28.06 | 10,000 | $280,568 | 861,391 | -1.1% |
| 2021-04-07 00:30 | 2021-04-05 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $29.93 | 1,750 | $52,378 | 595,416 | -0.3% |
| 2021-04-06 00:33 | 2021-04-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $29.49 | 2,200 | $64,880 | 208,286 | -1.0% |
| 2021-03-24 18:33 | 2021-03-22 | ARQT | Arcutis Biotherapeutics Inc. | CHAUDHURI BHASKAR | Director | Pharmaceutical Preparations | SALE | $31.10 | 10,000 | $311,021 | 871,391 | -1.1% |
| 2021-03-11 23:59 | 2021-03-10 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $32.90 | 1,750 | $57,575 | 86,715 | -2.0% |
| 2021-03-05 23:56 | 2021-03-05 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $30.55 | 1,750 | $53,463 | 597,166 | -0.3% |
| 2021-03-04 00:51 | 2021-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $35.19 | 2,107 | $74,136 | 566,216 | -0.4% |
| 2021-03-04 00:49 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | Turney Patricia A. | Officer; SVP, Operations | Pharmaceutical Preparations | SALE | $34.52 | 934 | $32,242 | 9,271 | -9.2% |
| 2021-03-04 00:47 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | Lock Kenneth A. | Officer; Chief Commercial Officer | Pharmaceutical Preparations | SALE | $34.20 | 933 | $31,908 | 22,167 | -4.0% |
| 2021-03-04 00:45 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $34.37 | 2,200 | $75,610 | 205,633 | -1.1% |
| 2021-03-04 00:48 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $34.20 | 773 | $26,440 | 24,425 | -3.1% |
| 2021-03-04 00:50 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $34.57 | 780 | $26,968 | 237,253 | -0.3% |
| 2021-02-24 23:33 | 2021-02-22 | ARQT | Arcutis Biotherapeutics Inc. | CHAUDHURI BHASKAR | Director | Pharmaceutical Preparations | SALE | $35.52 | 10,000 | $355,191 | 881,391 | -1.1% |
| 2021-02-13 01:32 | 2021-02-10 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $35.64 | 2,750 | $98,010 | 87,965 | -3.0% |
| 2021-02-09 00:00 | 2021-02-05 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $34.29 | 10,000 | $342,916 | 568,323 | -1.7% |
| 2021-02-03 19:24 | 2021-02-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $34.35 | 2,200 | $75,572 | 183,118 | -1.2% |
| 2021-02-03 19:23 | 2021-02-01 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $35.00 | 5,000 | $175,000 | 89,965 | -5.3% |
| 2021-02-03 03:39 | 2021-01-29 | ARQT | Arcutis Biotherapeutics Inc. | CHAUDHURI BHASKAR | Director | Pharmaceutical Preparations | SALE | $33.22 | 10,000 | $332,207 | 891,391 | -1.1% |
| 2021-01-22 00:41 | 2021-01-19 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $30.00 | 1,750 | $52,500 | 93,715 | -1.8% |
| 2021-01-07 23:13 | 2021-01-05 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $28.08 | 10,000 | $280,754 | 568,323 | -1.7% |
| 2021-01-06 21:16 | 2021-01-04 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $27.82 | 2,200 | $61,215 | 181,896 | -1.2% |
| 2020-12-16 23:14 | 2020-12-14 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $30.00 | 5,250 | $157,500 | 94,965 | -5.2% |
| 2020-12-16 23:15 | 2020-12-14 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $30.00 | 15,000 | $450,000 | 250,533 | -5.6% |
| 2020-12-04 03:40 | 2020-12-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $25.98 | 2,200 | $57,154 | 179,844 | -1.2% |
| 2020-11-05 00:33 | 2020-11-02 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $18.27 | 2,200 | $40,186 | 178,622 | -1.2% |
| 2020-10-07 00:23 | 2020-10-02 | ARQT | Arcutis Biotherapeutics Inc. | SILVERSTEIN JONATHAN | Director, 10% owner | Pharmaceutical Preparations | BUY | $25.00 | 496,000 | $12,400,000 | 902,286 | +122.1% |
| 2020-10-07 00:27 | 2020-10-02 | ARQT | Arcutis Biotherapeutics Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $25.00 | 496,000 | $12,400,000 | 902,286 | +122.1% |
| 2020-10-06 04:13 | 2020-10-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $27.65 | 2,200 | $60,829 | 177,400 | -1.2% |
| 2020-10-02 04:02 | 2020-09-29 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $30.00 | 3,000 | $90,000 | 566,928 | -0.5% |
| 2020-10-02 04:00 | 2020-09-29 | ARQT | Arcutis Biotherapeutics Inc. | Smither John W | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $30.00 | 1,750 | $52,500 | 98,715 | -1.7% |
| 2020-10-02 04:01 | 2020-09-29 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $30.00 | 15,000 | $450,000 | 264,279 | -5.4% |
| 2020-09-02 18:48 | 2020-09-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $24.38 | 2,200 | $53,643 | 176,178 | -1.2% |
| 2020-08-06 00:11 | 2020-08-03 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | OPT+S | $25.63 | 2,800 | $71,764 | 159,992 | -1.7% |
| 2020-02-07 00:26 | 2020-02-04 | ARQT | Arcutis Biotherapeutics Inc. | Bain Capital Life Sciences Investors, LLC | 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 294,117 | $4,999,989 | 3,979,292 | +8.0% |
| 2020-02-06 19:27 | 2020-02-04 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 500,000 | $8,500,000 | 10,542,790 | +5.0% |
| 2020-02-06 18:29 | 2020-02-04 | ARQT | Arcutis Biotherapeutics Inc. | Frazier Life Sciences VIII, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 500,000 | $8,500,000 | 10,542,790 | +5.0% |
| 2020-02-05 01:27 | 2020-02-03 | ARQT | Arcutis Biotherapeutics Inc. | SILVERSTEIN JONATHAN | Director, 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 558,888 | $9,501,096 | 176,500 | +100.0% |
| 2020-02-05 01:30 | 2020-02-03 | ARQT | Arcutis Biotherapeutics Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 558,888 | $9,501,096 | 176,500 | +100.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.